Antiepileptic prescribing to persons living with dementia residing in nursing homes: A tale of two indications

Antiepileptics are commonly prescribed to nursing home residents with Alzheimer's disease and related dementias (ADRD) but there is little scientific support for their use in this population. It is unclear whether different antiepileptics are targeting different indications.

[1]  P. Austin,et al.  Potential Unintended Consequences of Antipsychotic Reduction in Ontario Nursing Homes. , 2022, Journal of the American Medical Directors Association.

[2]  H. Kales,et al.  Pharmacological Management of Neuropsychiatric Symptoms of Dementia , 2020, Current Treatment Options in Psychiatry.

[3]  K. Langa,et al.  Prevalence of Psychotropic and Opioid Prescription Fills Among Community-Dwelling Older Adults With Dementia in the US. , 2020, JAMA.

[4]  A. Tricco,et al.  Assessing the validity of health administrative data compared to population health survey data for the measurement of low back pain , 2020, Pain.

[5]  H. Kales,et al.  Trends in Antipsychotic and Mood Stabilizer Prescribing in Long-Term Care in the U.S.: 2011-2014. , 2020, Journal of the American Medical Directors Association.

[6]  S. Crystal,et al.  National Partnership to Improve Dementia Care in Nursing Homes Campaign: State and Facility Strategies, Impact, and Antipsychotic Reduction Outcomes , 2020, Innovation in aging.

[7]  M. Choinière,et al.  Validity of Algorithms for Identification of Individuals Suffering from Chronic Noncancer Pain in Administrative Databases: A Systematic Review , 2020, Pain medicine.

[8]  V. Mor,et al.  Inappropriate Antipsychotic Use: The Impact of Nursing Home Socioeconomic and Racial Composition , 2020, Journal of the American Geriatrics Society.

[9]  V. Mor,et al.  The Minimum Data Set Agitated and Reactive Behavior Scale: Measuring Behaviors in Nursing Home Residents With Dementia. , 2019, Journal of the American Medical Directors Association.

[10]  A. Brett,et al.  A Clinical Overview of Off-label Use of Gabapentinoid Drugs. , 2019, JAMA internal medicine.

[11]  B. Bolea-Alamanac,et al.  Gabapentin and pregabalin to treat aggressivity in dementia: a systematic review and illustrative case report , 2019, British journal of clinical pharmacology.

[12]  S. Baillon,et al.  Valproate preparations for agitation in dementia. , 2018, The Cochrane database of systematic reviews.

[13]  Alyssa M. Peckham,et al.  Gabapentin for Off-Label Use: Evidence-Based or Cause for Concern? , 2018, Substance abuse : research and treatment.

[14]  D. Sclar,et al.  Gabapentin use, abuse, and the US opioid epidemic: the case for reclassification as a controlled substance and the need for pharmacovigilance , 2018, Risk management and healthcare policy.

[15]  Claire Chiang,et al.  Association of the Centers for Medicare & Medicaid Services’ National Partnership to Improve Dementia Care With the Use of Antipsychotics and Other Psychotropics in Long-term Care in the United States From 2009 to 2014 , 2018, JAMA internal medicine.

[16]  J. Devlin,et al.  Perceptions vs. evidence: therapeutic substitutes for antipsychotics in patients with dementia in long-term care , 2018, Aging & mental health.

[17]  M. Johansen.  Gabapentinoid Use in the United States 2002 Through 2015 , 2018, JAMA internal medicine.

[18]  A. Brett,et al.  Gabapentin and Pregabalin for Pain - Is Increased Prescribing a Cause for Concern? , 2017, The New England journal of medicine.

[19]  J. Bowblis,et al.  CMS Strategies To Reduce Antipsychotic Drug Use In Nursing Home Patients With Dementia Show Some Progress. , 2017, Health affairs.

[20]  Jeannie K. Lee,et al.  Variation in use of antipsychotic medications in nursing homes in the United States: A systematic review , 2017, BMC Geriatrics.

[21]  N. Herrmann,et al.  Trends in Psychotropic Dispensing Among Older Adults with Dementia Living in Long-Term Care Facilities: 2004-2013. , 2015, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[22]  M. Choinière,et al.  Is the Quebec provincial administrative database a valid source for research on chronic non‐cancer pain? , 2015, Pharmacoepidemiology and drug safety.

[23]  J. Shega,et al.  Optimal pharmacologic pain management in the older adult: an ongoing quagmire. , 2015, Pain medicine.

[24]  C. Lyketsos,et al.  Management of Neuropsychiatric Symptoms of Dementia in Clinical Settings: Recommendations from a Multidisciplinary Expert Panel , 2014, Journal of the American Geriatrics Society.

[25]  C. Jack,et al.  Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. , 2011, Archives of general psychiatry.

[26]  F. Verhey,et al.  Prescribing pattern of psychotropic drugs in nursing home residents with dementia , 2011, International Psychogeriatrics.

[27]  E. Dorsey,et al.  Impact of FDA black box advisory on antipsychotic medication use. , 2010, Archives of internal medicine.

[28]  M. Valenstein,et al.  Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. , 2007, The American journal of psychiatry.

[29]  A. Mack.  Examination of the Evidence for Off-Label Use of Gabapentin , 2003, Journal of managed care pharmacy : JMCP.

[30]  S. Soumerai,et al.  A critical analysis of studies of state drug reimbursement policies: research in need of discipline. , 1993, The Milbank quarterly.